How to Learn Eukaryotic Translesion DNA Synthesis: From PCNA Ubiquitination to Y-Family Polymerase Switching, REV1–Pol ζ Extension and Damage Tolerance

## Wait, What? Sometimes the Safest Immediate Choice Is to Copy Across a Damaged Base With a Less Accurate Polymerase Replicative DNA polymerases are highly accurate. That accuracy comes with a cost. Their active sites are geometrically strict. A bulky or distorted template base can stop them. The cell then faces two bad choices: 1. leave replication blocked; 2. use a more tolerant polymerase that may make a mistake. Translesion synthesis, or **TLS**, is the controlled use of specialized DNA polymerases to synthesize across damaged templates. The key principle is: > **continuity now, fidelity risk later** But TLS is not random desperation. Polymerase recruitment is regulated by PCNA ubiquitination and scaffold proteins. ## The One-Sentence Answer **Learn eukaryotic TLS as a regulated polymerase-switching pathway: damage-stalled replication generates RPA-coated ssDNA that recruits RAD18–RAD6 to monoubiquitinate PCNA at Lys164, ubiquitin-binding Y-family polymerases replace or coexist with replicative polymerases at the lesion, a lesion-specialized polymerase such as Pol η inserts across the damaged base, REV1 organizes polymerase exchange and Pol ζ often extends the distorted primer terminus, after which high-fidelity replication resumes and the mutation cost of bypass can be assessed separately from the survival benefit.** ## Learning Ladder **Beginner:** TLS lets DNA replication continue across some damaged bases using specialized polymerases. **Secondary / Pre-University:** DNA replication, mutations, DNA damage, polymerases, ubiquitin and repair. **Undergraduate:** PCNA, Lys164 ubiquitination, RAD6, RAD18, Pol η, Pol κ, Pol ι, REV1, Pol ζ/REV3–REV7 and PRIMPOL. **Advanced / Professional:** polymerase-switch models, UBZ/UBM and PIP motifs, insertion-versus-extension division of labour, lesion-specific fidelity, REV1 scaffolding, PCNA polyubiquitination/template switching, repriming and post-replicative gap filling, TLS mutational signatures and replication-fork versus gap-based damage tolerance. — ## Stage 1: Begin With the Difference Between Repair and Tolerance **DNA repair** removes or reverses a lesion. **DNA damage tolerance** allows replication to continue despite the lesion. TLS does not necessarily remove the damaged base. The lesion can remain after bypass and be repaired later. ## Stage 2: Replicative Polymerases Are Accurate Because They Are Selective Pol δ and Pol ε strongly favor correct Watson–Crick geometry, an undistorted template and a correctly paired primer terminus. This produces high fidelity. But unusual chemistry can jam the active site. ## Stage 3: A Stalled Polymerase Does Not Mean the Helicase Stops Instantly The CMG helicase and polymerase can become partially uncoupled. Single-stranded DNA accumulates. RPA coats that ssDNA. The stalled site becomes a signalling platform. ## Stage 4: RPA-Coated ssDNA Helps Recruit RAD18 RAD18 is an E3 ubiquitin ligase. Together with the E2 enzyme RAD6, it modifies PCNA. The key residue is: > **PCNA Lys164** ## Stage 5: PCNA Monoubiquitination Is a Damage-Tolerance Signal One ubiquitin attached to PCNA K164 changes which proteins bind the sliding clamp. TLS polymerases often contain PCNA-interacting peptide motifs and ubiquitin-binding UBZ or UBM domains. The clamp becomes a recruitment platform for specialized polymerases. ## Stage 6: Ubiquitinated PCNA Is Not a Command to Degrade PCNA Ubiquitin performs many non-proteasomal jobs. Here, monoubiquitin changes binding partners. This is signalling through protein modification. ## Stage 7: Polymerase Switching Is the Central TLS Event A high-fidelity polymerase stalls. A TLS polymerase gains access to the primer terminus. After bypass, the replicative polymerase returns. The critical question is: > **how does the cell expose the primer to a risky polymerase briefly, but not permanently?** ## Stage 8: One Model Uses Sequential Exchange In a sequential-switch model: > **replicative polymerase leaves → TLS polymerase enters → bypass occurs → TLS polymerase leaves → replicative polymerase returns** This is conceptually simple. ## Stage 9: Another Model Uses a Multi-Polymerase “Tool Belt” PCNA has multiple interaction surfaces. Replicative and TLS polymerases may coexist transiently. The primer terminus can be handed between nearby enzymes without complete dissociation from the clamp. Current evidence supports context-dependent switching rather than one universal geometry. ## Stage 10: Y-Family Polymerases Have More Open Active Sites Pol η, Pol ι and Pol κ belong to the Y family. Their active sites accommodate damaged or distorted bases better than replicative polymerases. The trade-off is lower geometric discrimination on undamaged DNA. ## Stage 11: Low Fidelity Can Be a Specialized Adaptation A polymerase that is “bad” on ordinary DNA can be excellent on one lesion. TLS should therefore be judged by: > **fidelity on the relevant damaged template**, not by general error rate alone. ## Stage 12: Pol η Is Specialized for UV Cyclobutane Pyrimidine Dimers DNA polymerase η can efficiently synthesize across a thymine–thymine cyclobutane pyrimidine dimer. Its spacious active site accommodates the linked bases. When the lesion is a correctly structured CPD, Pol η can bypass it relatively accurately. ## Stage 13: Losing Pol η Can Make UV Mutagenesis Worse This seems paradoxical. A lower-fidelity polymerase is missing, yet mutations rise. Why? Other polymerases bypass the UV lesion less accurately. The correct specialist is safer than the wrong backup. ## Stage 14: XP-Variant Biology Demonstrates Lesion-Specific TLS POLH defects make cells especially vulnerable to mutagenic consequences of UV lesion bypass. This is mechanistic evidence that polymerase specialization matters. ## Stage 15: Pol κ Has Different Lesion Preferences Pol κ can bypass selected bulky minor-groove adducts and other lesions more effectively than Pol η. Different Y-family polymerases solve different geometries. There is no universal “TLS polymerase”. ## Stage 16: Pol ι Uses Unusual Base-Pairing Geometry Pol ι can employ Hoogsteen-like base pairing in its active site. This can help with selected damaged templates but gives unusual fidelity patterns. Active-site architecture determines lesion preference. ## Stage 17: REV1 Is Both a Polymerase and a Scaffold REV1 has a specialized dCMP-transferase catalytic activity. But much of its importance in mammalian TLS comes from protein interactions. REV1 binds multiple Y-family polymerases and Pol ζ-related factors. ## Stage 18: REV1 Organizes Polymerase Exchange The REV1 C-terminal region acts as a docking hub. A lesion-insertion polymerase can bind. Then an extension polymerase can take over. The scaffold creates an ordered bypass sequence. ## Stage 19: Insertion and Extension Can Be Different Jobs Some TLS events use: 1. **inserter polymerase** — places a nucleotide opposite the lesion. 2. **extender polymerase** — extends from the distorted primer terminus. Pol ζ is a major extender. ## Stage 20: Pol ζ Is a B-Family Polymerase Specialized for Extension Pol ζ contains REV3 as its catalytic subunit and REV7 plus accessory subunits. Its active site is better at extending abnormal primer termini than many replicative polymerases. It is not necessarily the best enzyme for inserting directly opposite every lesion. ## Stage 21: TLS Can Therefore Be a Two-Polymerase Relay A common conceptual route is: > **Y-family polymerase inserts → REV1 scaffold coordinates handoff → Pol ζ extends → replicative polymerase resumes** This is a relay race, not one enzyme doing the entire bypass. ## Stage 22: PCNA Ubiquitination Is Important but Not the Only Recruitment Mechanism TLS polymerases also bind PCNA directly. REV1 scaffolding and local protein concentrations matter. Some TLS can occur with reduced PCNA ubiquitination. The modification strongly biases the network but does not define every event absolutely. ## Stage 23: PCNA Polyubiquitination Can Promote an Alternative to TLS Extension of ubiquitin chains on PCNA is associated with **template switching** in many systems. Template switching uses information from the newly synthesized sister strand. This can bypass a lesion without copying directly across it. ## Stage 24: TLS and Template Switching Are Competing Damage-Tolerance Strategies **TLS** – copy across lesion; – potentially mutagenic. **template switching** – use sister information; – often higher fidelity. PCNA ubiquitin architecture contributes to pathway choice. ## Stage 25: PRIMPOL Can Reprime Downstream of a Lesion Instead of bypassing immediately at the fork, PRIMPOL can create a new primer downstream. Replication resumes beyond the lesion. A single-stranded gap is left behind. ## Stage 26: Many TLS Events May Occur Behind the Fork The old textbook picture shows TLS directly at a stalled replication fork. Modern work emphasizes substantial **post-replicative gap filling**. The fork can move on first. TLS repairs the continuity problem later. ## Stage 27: Fork Bypass and Gap Filling Must Be Distinguished Experimentally A TLS polymerase focus at damaged DNA does not prove whether bypass occurred at the fork or in a gap behind the fork. Timing and replication intermediates matter. ## Stage 28: Gap Formation Can Protect Fork Progress but Create a New Liability Repriming prevents prolonged helicase/polymerase arrest. But ssDNA gaps are fragile, signalling-active and recombination substrates. Damage tolerance trades one problem for another manageable intermediate. ## Stage 29: REV1–Pol ζ Is Especially Important for Mutagenic TLS Many damage-induced mutations depend on REV1 and Pol ζ. These proteins therefore connect lesion survival and mutation generation. A pathway can increase short-term survival while raising long-term genomic variation. ## Stage 30: Mutation Is Not the Purpose of TLS The purpose is replication continuity. Mutation is a risk caused by copying damaged information with flexible polymerases. Selection acts on survival/fidelity trade-offs, not on a goal to “create mutations”. ## Stage 31: TLS Polymerases Must Be Restricted on Undamaged DNA If Pol η/κ/ι or Pol ζ copied large portions of normal genome, mutation rates would rise. Cells therefore control recruitment, abundance, degradation, PCNA access and cell-cycle timing. Specialist enzymes are useful only when localized. ## Stage 32: Deubiquitination Resets PCNA USP1 and other regulatory systems remove ubiquitin from PCNA. The clamp can return toward its ordinary replication state. Damage tolerance needs an off-switch. ## Stage 33: DNA Repair Can Remove the Lesion Later After TLS fills past a lesion, nucleotide excision repair or other pathways may remove the original damaged base. Tolerance and repair can happen in sequence. A complete cellular response can therefore be: > **bypass now → repair later** ## Stage 34: TLS Can Leave Mutational Signatures Different lesions and polymerases produce characteristic mutation biases. Genome sequencing can therefore infer contributions of particular damage/tolerance processes. But no mutation signature is perfectly unique to one polymerase. ## Stage 35: Structure Explains Why Lesion Specificity Exists High-resolution structures show open Y-family active sites, lesion accommodations, unusual base-pair geometry and Pol ζ extension capacity. Structural biology turns “error-prone” into a specific geometric explanation. ## Stage 36: Biochemistry Must Be Interpreted With Polymerase Concentration A TLS polymerase can bypass a lesion in vitro at high concentration. That does not prove it is the physiological enzyme. In cells, recruitment hierarchy and competition determine access. ## Stage 37: Survival and Fidelity Must Be Measured Separately A TLS pathway can improve survival but increase mutation rate. Another can reduce mutation but slow replication. The correct outcome depends on which variable is being tested. ## Stage 38: The Professional Question Is a Stall–Switch–Bypass–Reset Closure Test Ask: > **What lesion stalled the replicative polymerase, whether ssDNA/RPA recruited RAD18–RAD6, what PCNA ubiquitin state formed, which TLS polymerase inserted opposite the lesion, whether REV1/Pol ζ performed extension, whether bypass occurred at the fork or in a post-replicative gap, when PCNA and polymerase usage reset, and what survival-versus-mutation cost resulted.** ## Evidence: What Proves What? ### Stalling – lesion-containing templates; – fork progression; – RPA/ssDNA; – polymerase arrest. ### PCNA signalling – K164 mutants; – RAD18/RAD6 perturbation; – ubiquitin mapping. ### Polymerase recruitment – live imaging; – PIP/UBZ/UBM mutants; – REV1 interactions. ### Lesion bypass – purified-polymerase assays; – sequencing of bypass products; – gap-filling measurements. ### Biological cost – survival; – mutation frequency; – mutational signatures; – replication stress. ## Connections Worth Making ### DNA Replication TLS is triggered when high-fidelity replication encounters template damage. ### Ubiquitin Biology PCNA monoubiquitination changes polymerase recruitment rather than causing degradation. ### DNA Repair TLS tolerates lesions that repair pathways may remove later. ### Homologous Recombination Template switching and ssDNA-gap repair provide alternatives/interactions with TLS. ### Evolution TLS trades short-term replication continuity against mutation risk. ## Misconceptions Worth Hunting – **“TLS repairs the damaged base.”** It usually copies across it; the lesion can remain. – **“TLS polymerases are simply defective versions of normal polymerases.”** Their open active sites are specialized adaptations. – **“Low fidelity means Pol η is always dangerous.”** It can be the most accurate polymerase for UV CPDs. – **“PCNA ubiquitination marks PCNA for proteasomal degradation.”** K164 monoubiquitin is a recruitment signal. – **“One TLS polymerase performs every bypass.”** Lesion specificity and insertion/extension division of labour matter. – **“REV1 is important only because it inserts cytosine.”** Its scaffold role is central. – **“TLS always occurs at the stalled fork.”** Post-replicative gap filling is important. – **“Damage-induced mutation is an adaptive goal.”** It is a risk of damage tolerance. ## Transfer Check PCNA K164 cannot be ubiquitinated. What class of regulated recruitment becomes weaker? **Ubiquitin-dependent TLS polymerase recruitment.** A UV CPD stalls Pol δ, but Pol η is available. Can bypass be relatively accurate despite using a Y-family polymerase? **Yes.** An inserter places a nucleotide opposite the lesion but cannot extend the distorted terminus. Which polymerase class may be recruited next? **An extender such as Pol ζ.** PRIMPOL reprimes downstream. Has the lesion been bypassed chemically? **Not yet; a gap has been left for later processing.** TLS increases survival but mutation frequency rises. Is that internally consistent? **Yes.** ## How We Know the Learning Has Held A learner should be able to distinguish repair from damage tolerance; explain stalled-fork ssDNA/RPA and RAD18–RAD6; explain PCNA K164 monoubiquitination; describe Y-family polymerase specialization; explain Pol η/κ/ι differences conceptually; explain REV1 and Pol ζ; distinguish insertion from extension; explain template switching and PRIMPOL repriming; and evaluate TLS through both replication continuity and mutation cost. ## Model Limits Polymerase switching is not captured by one universal sequential model. PCNA ubiquitination is important but not absolutely required for every TLS event. Lesion specificity overlaps among polymerases. Much TLS may occur in gaps behind forks rather than directly at stalled forks. In-vitro polymerase fidelity depends strongly on sequence and reaction conditions. Mutational signatures reflect multiple interacting repair/tolerance pathways. > **Professional TLS science keeps lesion identity + fork/gap context + PCNA ubiquitin state + polymerase identity + insertion/extension division + reset timing + survival + mutation cost visible together.** ## Teaching Guide Teach in this order: **replicative polymerase stall → RPA/ssDNA → RAD18/RAD6 → PCNA K164-Ub → polymerase switch → Y-family geometry → Pol η → Pol κ/ι → REV1 scaffold → Pol ζ extension → replicative polymerase return → template switching → PRIMPOL gaps → mutation/survival trade-off → model limits.** Begin with: > “Why would a cell deliberately replace its most accurate DNA polymerase with a less accurate one?” ## Connect This to the eduKate Learning Estate – [DNA Replication and Repair](https://edukatesengkang.com/2026/08/28/how-to-learn-dna-replication-repair-genome-stability/) – [Bacterial Nucleotide Excision Repair](https://edukatesengkang.com/2026/09/01/how-to-learn-bacterial-nucleotide-excision-repair/) – [RAD51–BRCA Homologous Recombination](https://edukatesengkang.com/2026/09/01/how-to-learn-rad51-brca-homologous-recombination/) – [Ribonucleotide Reductases](https://edukatesengkang.com/2026/09/01/how-to-learn-ribonucleotide-reductases/) These remain broader or adjacent canonical owners. This article owns **eukaryotic PCNA-ubiquitin-directed translesion synthesis and lesion-bypass polymerase switching**. ## Research Foundations and Further Learning – Reviews of ubiquitin/SUMO pathways in DNA replication and replication-coupled repair. – Structural and biochemical work on PCNA K164 ubiquitination and RAD18–RAD6. – Modern structures of Pol η bypassing UV cyclobutane pyrimidine dimers. – REV1 interaction/scaffold and Pol ζ extension studies. – Work comparing sequential polymerase switching with multi-polymerase “tool-belt” models. – PRIMPOL and post-replicative ssDNA-gap literature. – Reviews of translesion-polymerase mutagenesis, lesion specificity and DNA-damage tolerance. ## The Quiet Ending The beginner asks: “How can DNA replication continue if the next base is damaged?” The developing molecular biologist asks: “Why does ubiquitin on PCNA recruit a different polymerase instead of destroying the clamp?” The advanced learner asks: “Why can an inaccurate polymerase be the most accurate choice for one particular lesion?” And the professional asks: > **Can we reconstruct one lesion-bypass event from fork stalling and PCNA modification through the exact insertion/extension polymerases to a resumed high-fidelity fork—and quantify separately the survival benefit and mutational price of that decision?**